Company: NCEL
Filing Date: 2025-03-31
Form Type: 425
Source: 0001213900-25-025889
Chunk: 256

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: 425
Chunk 256
---
 such number of Warrant Shares                                                                           
 as is necessary, in accordance with the formula set forth in subsection 2.3, to exercise this Warrant with respect to the maximum number 
 of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2.3.                                   |

(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be
delivered to the following DWAC Account Number:

_______________________________

_______________________________

_______________________________

(4) The undersigned is an
“accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

<div align='center'>14</div>

Exhibit 2.4.6

<div align='center'>ASSIGNMENT FORM</div>

(To assign the foregoing Warrant,
execute this form and supply required information. Do not use this form to exercise the Warrant to purchase Common Shares.)

FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to

Name:

Address:

Phone Number:

Email Address:

Date:

Holder’s Signature:

Holder’s Address:

<div align='center'>15</div>

Exhibit 99.5

<div align='center'>NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

The equity financing is at a 10% premium to the market share price 1</div>

ZÜRICH, Switzerland, March 31,
2025 - NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (“NLS” or the “Company”), a Swiss clinical-stage
biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced the closing
of a $2 million equity financing of preferred shares at a stated value of $1.65 per share, with a potential second closing of up to an
additional $1 million of preferred shares at a purchase price of $1.65 per share. The second closing of $1 million of preferred shares
is subject to shareholder approval. The offering closed on Friday, March 28, 2025, and the gross proceeds to the Company from the offering
were $2